[{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"PRV-101","moa":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ SVB Leerink"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PRV-015","moa":"IL-15","graph1":"Immunology","graph2":"Phase II","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Beyond Celiac","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15","graph1":"Immunology","graph2":"Phase II","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Provention Bio \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Provention Bio \/ Provention Bio"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15","graph1":"Immunology","graph2":"Phase II","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Provention Bio \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Provention Bio \/ Provention Bio"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"PRV-101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ SVB Leerink"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"PRV-3279","moa":"CD32B","graph1":"Immunology","graph2":"Phase I","graph3":"Provention Bio","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.28999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Provention Bio \/ Huadong","highestDevelopmentStatusID":"6","companyTruncated":"Provention Bio \/ Huadong"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"PRV-101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Sanofi"},{"orgOrder":0,"company":"Provention Bio","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.40000000000000002,"dosageForm":"Injection","sponsorNew":"Provention Bio \/ Provention Bio","highestDevelopmentStatusID":"12","companyTruncated":"Provention Bio \/ Provention Bio"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Teplizumab-mzwv","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Provention Bio \/ Hercules Capital"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Teplizumab-mzwv","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Provention Bio \/ Sanofi"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":2.8999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":2.8999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Provention Bio \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Provention Bio \/ Sanofi"},{"orgOrder":0,"company":"Provention Bio","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Teplizumab-mzwv","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Provention Bio \/ Provention Bio","highestDevelopmentStatusID":"12","companyTruncated":"Provention Bio \/ Provention Bio"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":2.8999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":2.8999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Provention Bio \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Provention Bio \/ Sanofi"}]

Find Clinical Drug Pipeline Developments & Deals by Provention Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Through the acquisition of Provention Bio, Sanofi adds to its portfolio, TZIELD (teplizumab-mzwv), a CD3-directed antibody, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).

                          Brand Name : Tzield

                          Molecule Type : Large molecule

                          Upfront Cash : $2,900.0 million

                          April 27, 2023

                          Lead Product(s) : Teplizumab

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Sanofi

                          Deal Size : $2,900.0 million

                          Deal Type : Acquisition

                          Provention Bio

                          02

                          Details : Through the acquisition of Provention Bio, Sanofi adds to its portfolio, TZIELD (teplizumab-mzwv), a CD3-directed antibody, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).

                          Brand Name : Tzield

                          Molecule Type : Large molecule

                          Upfront Cash : $2,900.0 million

                          March 13, 2023

                          Lead Product(s) : Teplizumab

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Sanofi

                          Deal Size : $2,900.0 million

                          Deal Type : Acquisition

                          Provention Bio

                          03

                          Details : The financing will be used to support the commercial launch of TZIELD (teplizumab-mzwv). TZIELD is a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years and older with Stage 2 T1D.

                          Brand Name : Tzield

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 13, 2023

                          Lead Product(s) : Teplizumab-mzwv

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Sanofi

                          Deal Size : $35.0 million

                          Deal Type : Agreement

                          Provention Bio

                          04

                          Details : Tzield (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years and older with Stage 2 T1D.

                          Brand Name : Tzield

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 02, 2023

                          Lead Product(s) : Teplizumab-mzwv

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Hercules Capital

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          Provention Bio

                          05

                          Details : Under the agreement, AGC Biologics will manufacture TZIELD™ (teplizumab-mzwv), a new T1D treatment. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older.

                          Brand Name : Tzield

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 24, 2023

                          Lead Product(s) : Teplizumab-mzwv

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Recipient : AGC Biologics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Provention Bio

                          06

                          Details : Under the terms of the agreements held in 2018, Provention has acquired all rights to Tzield (teplizumab) to be further developed as PRV-031 and licensing rights to MGD010 for development as PRV-3279.

                          Brand Name : Tzield

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 17, 2022

                          Lead Product(s) : Teplizumab

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Recipient : MacroGenics

                          Deal Size : $395.0 million

                          Deal Type : Agreement

                          Provention Bio

                          07

                          Details : Tzield (teplizumab-mzwv) binds to certain immune system cells and delays progression to stage 3 type 1 diabetes. Tzield may deactivate the immune cells that attack insulin-producing cells, while increasing the proportion of cells that help moderate the i...

                          Brand Name : Tzield

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 17, 2022

                          Lead Product(s) : Teplizumab

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Provention Bio

                          08

                          Details : Teplizumab (PRV-031), is an investigational anti-CD3 monoclonal antibody that is being evaluated for the delay of clinical type 1 diabetes (T1D) in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies.

                          Brand Name : PRV-031

                          Molecule Type : Large molecule

                          Upfront Cash : $20.0 million

                          October 06, 2022

                          Lead Product(s) : Teplizumab

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Sanofi

                          Deal Size : $55.0 million

                          Deal Type : Agreement

                          Provention Bio

                          09

                          Details : PRV-101 is an investigational polyvalent vaccine being developed for the prevention of acute coxsackievirus B (CVB) infection and the potential delay or prevention of type 1 diabetes (T1D) and celiac disease.

                          Brand Name : PRV-101

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 28, 2022

                          Lead Product(s) : PRV-101

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Provention Bio

                          10

                          Details : Teplizumab, an investigational anti-CD3 mAb developed for delay of clinical type 1 diabetes at-risk individuals, company resubmitted BLA for teplizumab has been considered a complete, class 2 response by USFDA.

                          Brand Name : PRV-031

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 21, 2022

                          Lead Product(s) : Teplizumab

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Provention Bio